diffuse large B-cell lymphoma
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Roche opens new Swiss Institute of Human Biology research facility
The new building is part of a 1.5bn euro site investment
Roche’s Columvi improves survival in large B-cell lymphoma
Approximately 160,000 people are diagnosed with this aggressive form of cancer each year
Roche receives FDA clearance for whooping cough test
There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
Genentech announces positive clinical results for BTK inhibitor MS treatment
Multiple sclerosis affects more than 2.9 million people globally
Roche’s small cell lung cancer therapy approved by FDA
This is the first and only approved combination therapy for extensive-stage small cell lung cancer
Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma
The recommendation for the subcutaneous formulation follows encouraging trial data